Skip to content

Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington’s disease (HD): A prospective, randomised, controlled, international, multi-centre study

Deep Brain Stimulation (DBS) of the Globus pallidus (GP) in Huntington’s disease (HD): A prospective, randomised, controlled, international, multi-centre study - HD-DBS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00006785
Enrollment
50
Registered
2014-09-24
Start date
2015-03-18
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G10

Interventions

Group 1: Pallidal deep brain stimulation during the whole study (2x12weeks) Group 2: No pallidal deep brain stimulation for 12 weeks following 12 weeks with stimulation.

Sponsors

Universität Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: •Clinically symptomatic and genetically confirmed HD (number of CAG repeats = 36) •Age =18 years •Moderate stage of the disease (UHDRS motor score = 30) •Chorea despite best medical treatment (UHDRS chorea subscore = 10) •Mattis Dementia Rating Scale = 120 (or > 80% of items testable independently from motor impairment) •Patient has stable medication prior six weeks before inclusion •Signed informed consent

Exclusion criteria

Exclusion criteria: •Juvenile HD (Westphal variant) or predominant bradykinesia •Postural instability with UHDRS retropulsion score > 2 •Severe comorbidity compromising operability and/or life expectancy and/or quality of life during the trial duration (e.g. cancer with life expectancy < 6 months, NYHA 3 and 4 rising the anaesthetic risk according to the anaesthesiologist) •Acute suicidality •Acute psychosis (symptoms within previous 6 months) •Participation in any interventional clinical trial within 2 months before baseline •Cortical atrophy grade 3 •Patients with risk of coagulopathies and/or increased risk of haemorrhage •Patients with an implanted pacemaker or defibrillator •Pregnancy •lactation

Design outcomes

Secondary

MeasureTime frame
Motor function: -Difference in the Unified Huntington's Disease Rating Scale (UHDRS) chorea subscore (items 14-20) -Difference in the UHDRS bradykinesia subscore (items 22-25 and 27-29) -Difference in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) motor score -Difference in the Q-Motor "choreomotography” test (Reilmann Battery) -Difference in the Q-Motor “digitomotography” test (Reilmann Battery) i.Digitomotography – IOI-variability ii.Dysdiadochomotography – IOI-variability iii.Manumotography – GFV iv.Choreomotography – Orientation-index v.Pedomotography – IOI-variability Cognition: -Difference in the Mattis Dementia Rating Scale (MDRS) -Difference in the Verbal Fluency Test (formal lexical, categorical, category change) -Difference in the Symbol Digit Modalities Test (SDMT) -Difference in STROOP word reading, colour naming and colour of the word naming Psychiatry / Emotion: -Difference in the Hospital Anxiety and Depression Scale combined with Snaith Irritability Scale (HADS-SIS) -Difference in the Problem Behaviours Assessment Short Form (PBA-s) Quality of Life: -Difference in the Short Form (36) Health Survey (SF-36) -Difference in the Clinical Global Impression Scale (CGI)

Primary

MeasureTime frame
Difference between the groups in the UHDRS (Unified Huntingon's Disease Rating Scale) total motor score (UHDRS-TMS) at 12 weeks postoperatively compared to baseline .

Countries

Austria, France, Germany

Contacts

Public ContactJan Vesper

Funktionelle Neurochirurgie und StereotaxieNeurochirurgische Klinik,Universitätsklinikum DüsseldorfAmbulanz/Sekr.: +49 211 81 16058

jan.vesper@uniklinik-duesseldorf.de+49 211 81 18408

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026